REL and breast cancer: Santolla M.F. et al. demonstrated that LNA-i-miR-221, a novel antisense oligonucleotide (ASO), was developed to specifically inhibit miR-221 oncogenic activity [66,67,68,69,70,71] and reverts the A20 downregulation and upregulation of c-Rel induced by miR-221 in breast cancer cell models.